Independent Auditor's Report and Consolidated Financial Statements

June 30, 2021 and 2020



University of Kansas Medical Center Research Institute, Inc. June 30, 2021 and 2020

Contents

Independent Auditor's Report1
Consolidated Financial Statements
Statements of Financial Position
Statements of Activities
Statements of Functional Expenses
Statements of Cash Flows
Notes to Financial Statements9
Supplementary Information
Consolidating Statement of Financial Position as of June 30, 2021
Consolidating Statement of Activities for the Year Ended June 30, 2021
Schedule of Expenditures of Federal Awards
Notes to Schedule of Expenditures of Federal Awards
Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards – Independent Auditor's Report
Report on Compliance for the Major Federal Program and Report on Internal Control Over Compliance – Independent Auditor's Report41
Schedule of Findings and Questioned Costs44
Summary Schedule of Prior Audit Findings49
Corrective Action Plan50



Independent Auditor's Report

Board of Directors University of Kansas Medical Center Research Institute, Inc. Kansas City, Kansas

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of the University of Kansas Medical Center Research Institute, Inc., which comprise the consolidated statements of financial position as of June 30, 2021 and 2020, and the related consolidated statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Board of Directors University of Kansas Medical Center Research Institute, Inc. Page 2

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the University of Kansas Medical Center Research Institute, Inc. as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary information, including the consolidating financial statements and the schedule of expenditures of federal awards as required by Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles and Audit Requirements for Federal Awards, as listed in the table of contents, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 6, 2021 on our consideration of the University of Kansas Medical Center Research Institute, Inc.'s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University of Kansas Medical Center Research Institute, Inc.'s internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University of Kansas Medical Center Research Institute, Inc.'s internal control over financial reporting and compliance.

Kansas City, Missouri October 6, 2021

BKD.LLP

Consolidated Statements of Financial Position June 30, 2021 and 2020

Assets

7.050.0	2021	2020
Cash and cash equivalents	\$ 5,937,289	\$ 9,855,304
Accounts receivable, net	8,809,868	7,067,261
Grants receivable	29,233,437	17,596,616
Contributions receivable	2,937,751	3,479,432
Investments	97,949,966	70,525,604
Precede Fund, L.C. investments	431,370	521,677
Kansas Life Sciences Development Company, Inc. (KLSD) investment	352,321	1,315,709
Interest receivable	241,981	199,531
Prepaid expenses	433,869	239,613
Property and equipment, net	488,702	266,305
Total assets	\$ 146,816,554	\$ 111,067,052
Liabilities and Net Assets		
Liabilities		
Accounts payable	\$ 7,825,777	\$ 4,389,714
Accrued expenses	6,343,557	3,708,124
Deferred revenue	5,414,560	3,228,600
Total liabilities	19,583,894	11,326,438
Net Assets		
Without donor restrictions	119,767,417	92,726,921
With donor restrictions	7,465,243	7,013,693
Total net assets	127,232,660	99,740,614
Total liabilities and net assets	\$ 146,816,554	\$ 111,067,052

Consolidated Statement of Activities Year Ended June 30, 2021

		thout Donor estrictions		ith Donor strictions		Total
Revenues, Gains and Other Support						
Direct research income - grants	\$	71,418,206	\$	_	\$	71,418,206
Direct research income - contracts	Ψ	6,734,350	Ψ	_	Ψ	6,734,350
Total direct research income		78,152,556		-		78,152,556
Clinical trials		31,985,435		_		31,985,435
Clinical trial IRB and administrative fees		3,452,747		-		3,452,747
Facilities and administrative revenue - direct						
research income - grants		26,223,965		-		26,223,965
Facilities and administrative revenue - direct						
research income - contracts		777,493		_		777,493
Facilities and administrative revenue - clinical trials		10,619,048		_		10,619,048
Total facilities and administrative revenue		37,620,506		-		37,620,506
Contributions		5,022,510		4,727,815		9,750,325
Research Properties, Inc. rental income		306,636				306,636
Support for KU Center for Technology						,
Commercialization, Inc.		740,000		_		740,000
Royalties and technology income		1,866,778		_		1,866,778
Net investment loss		(718,736)		_		(718,736)
Other income		27,316		_		27,316
Net assets released from restrictions		4,276,265		(4,276,265)		-
Total revenues, gains and other support		162,732,013		451,550		163,183,563
Expenses						
Direct research		120,872,388		_		120,872,388
Facilities		8,658		_		8,658
University support		3,466,664		_		3,466,664
Research Properties, Inc.		306,233		_		306,233
KU Center for Technology Commercialization, Inc.		200,222				200,222
Royalties and technology		2,141,023		_		2,141,023
Kansas Life Sciences Development		2,111,023				2,111,025
Company, Inc.		153,195		_		153,195
Management and general		8,743,356		_		8,743,356
Management and general		0,743,330				0,743,330
Total expenses		135,691,517	1			135,691,517
Change in Net Assets		27,040,496		451,550		27,492,046
Net Assets, Beginning of Year		92,726,921		7,013,693		99,740,614
Net Assets, End of Year	\$	119,767,417	\$	7,465,243	\$	127,232,660

Consolidated Statement of Activities Year Ended June 30, 2020

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues, Gains and Other Support			
Direct research income - grants	\$ 67,701,549	\$ 133,311	\$ 67,834,860
Direct research income - contracts	5,711,245	-	5,711,245
Total direct research income	73,412,794	133,311	73,546,105
CIT : 14 : 1	21.020.207		21.020.205
Clinical trials	21,829,285	-	21,829,285
Clinical trial IRB and administrative fees	2,216,849	-	2,216,849
Facilities and administrative revenue - direct			
research income - grants	22,510,843	-	22,510,843
Facilities and administrative revenue - direct			
research income - contracts	669,815	-	669,815
Facilities and administrative revenue - clinical trials	6,104,215		6,104,215
Total facilities and administrative revenue	29,284,873	-	29,284,873
Contributions	6,724,022	3,782,315	10,506,337
Research Properties, Inc. rental income	271,682	· · · · -	271,682
Support for KU Center for Technology	,		,
Commercialization, Inc.	1,187,375	-	1,187,375
Royalties and technology income	1,706,729	-	1,706,729
Net investment return	4,026,731	-	4,026,731
Other income	110,914	-	110,914
Net assets released from restrictions	2,898,534	(2,898,534)	
Total revenues, gains and other support	143,669,788	1,017,092	144,686,880
Expenses			
Direct research	113,122,064	-	113,122,064
Facilities	312,831	-	312,831
University support	13,493,316	-	13,493,316
Research Properties, Inc.	395,841	-	395,841
KU Center for Technology Commercialization, Inc.			
Royalties and technology	2,380,531	-	2,380,531
Kansas Life Sciences Development			
Company, Inc.	2,974	-	2,974
Management and general	6,926,447		6,926,447
Total expenses	136,634,004		136,634,004
Change in Net Assets before Contribution for			
and Gain on Repayment of Debt	7,035,784	1,017,092	8,052,876
Contribution for and Gain on Repayment of Debt	12,521,631		12,521,631
Change in Net Assets	19,557,415	1,017,092	20,574,507
Net Assets, Beginning of Year	73,169,506	5,996,601	79,166,107
Net Assets, End of Year	\$ 92,726,921	\$ 7,013,693	\$ 99,740,614

Consolidated Statement of Functional Expenses Year Ended June 30, 2021

					Prog	ram Services					Supp	ort Services		
		Direct Research	Facilities	Iniversity Support		Research perties, Inc.		Royalties and Technology KUCTC	KLSD	Total Program Services		nagement d General	l	Total Expenses
Personnel	\$	52,053,366	\$ _	\$ -	\$	-	\$	630,196	\$ -	\$ 52,683,562	\$	5,494,534	\$	58,178,096
Fringe benefits		14,132,414	-	-		993		169,255	-	14,302,662		1,492,807		15,795,469
Contract services		2,040,411	-	-		-		-	-	2,040,411		13,729		2,054,140
Travel, food and meetings		133,800	-	-		-		307	-	134,107		352		134,459
Professional fees		10,496,315	-	-		104,500		423,382	-	11,024,197		766,198		11,790,395
Subaward payments		17,531,678	-	-		-		-	-	17,531,678		-		17,531,678
Supplies		8,208,130	-	-		1,047		78	-	8,209,255		50,765		8,260,020
Depreciation		-	8,658	-		-		-	-	8,658		-		8,658
Payments to students and subjects		2,068,665	-	-		-		-	-	2,068,665		1,000		2,069,665
Fees, dues and charges		7,149,056	-	-		67		234,056	153,195	7,536,374		575,327		8,111,701
Capital asset donation to KUMC		2,641,811	-	-		-		-	-	2,641,811		8,658		2,650,469
Equipment and other non-capital items		607,709	-	-		-		-	-	607,709		27,705		635,414
Services		2,958,731	-	-		199,626		2,561	-	3,160,918		291,950		3,452,868
F&A transfer for University operations		-	-	3,466,664		-		-	-	3,466,664		-		3,466,664
Royalty distributions		-	-	-		-		681,188	-	681,188		-		681,188
Bad debt expense		841,941	-	-		-		-	-	841,941		-		841,941
Insurance	_	8,361	 	 			_	-	 	 8,361		20,331		28,692
Totals	\$	120,872,388	\$ 8,658	\$ 3,466,664	\$	306,233	\$	2,141,023	\$ 153,195	\$ 126,948,161	\$	8,743,356	\$	135,691,517

Consolidated Statement of Functional Expenses Year Ended June 30, 2020

					Pro	gram Services					Sup	port Services		
	 Direct Research	Facilities	ı	University Support		Research operties, Inc.		Royalties and Technology KUCTC	KLSD	Total Program Services		anagement nd General	ı	Total Expenses
Personnel	\$ 49,441,652	\$ -	\$	-	\$	-	\$	685,274	\$ _	\$ 50,126,926	\$	4,264,576	\$	54,391,502
Fringe benefits	11,462,489	-		-		-		144,621	-	11,607,110		1,012,726		12,619,836
Contract services	359,338	-		-		-		-	-	359,338		20,000		379,338
Travel, food and meetings	1,752,378	-		-		-		5,668	-	1,758,046		59,212		1,817,258
Professional fees	2,098,658	-		-		126,562		729,368	2,808	2,957,396		180,666		3,138,062
Subaward payments	14,098,735	-		-		-		-	-	14,098,735		212,355		14,311,090
Supplies	7,065,301	-		-		-		170	-	7,065,471		60,312		7,125,783
Payments to students and subjects	1,880,977	-		-		-		-	-	1,880,977		-		1,880,977
Fees, dues and charges	18,389,902	-		-		-		4,253	166	18,394,321		660,342		19,054,663
Capital asset donation to KUMC	3,794,017	-		-		-		-	-	3,794,017		-		3,794,017
Equipment and other non-capital items	613,612	-		-		-		-	-	613,612		2,768		616,380
Services	2,165,005	-		-		269,279		152,997	-	2,587,281		56,821		2,644,102
F&A transfer for University operations	-	-		13,493,316		-		-	-	13,493,316		-		13,493,316
Royalty distributions	-	-		-		-		658,180	-	658,180		-		658,180
Interest expense	-	312,831		-		-		-	-	312,831		-		312,831
Bad debt expense	-	-		-		-		-	-	-		378,402		378,402
Insurance	 -	 -		-			_	-		 -		18,267		18,267
Totals	\$ 113,122,064	\$ 312,831	\$	13,493,316	\$	395,841	\$	2,380,531	\$ 2,974	\$ 129,707,557	\$	6,926,447	\$	136,634,004

Consolidated Statements of Cash Flows Years Ended June 30, 2021 and 2020

	2021	2020
Operating Activities		
Cash received from direct research, clinical trials, facility and		
administrative fees and contributions	\$ 150,309,782	\$ 137,240,301
Cash received from royalties, technology, rents and other	2,940,730	3,518,473
Investment income received	2,363,033	2,433,628
Cash paid to employees and suppliers	(129,805,619)	(138,791,645)
Interest paid	<u> </u>	(515,409)
Net cash provided by operating activities	25,807,926	3,885,348
Investing Activities		
Purchase of property and equipment	(231,055)	-
Purchase of investments	(64,661,903)	(25,742,233)
Proceeds from disposition of investments	35,167,017	29,406,695
Net cash provided by (used in) investing activities	(29,725,941)	3,664,462
Financing Activities		
Principal payments on bonds payable		(940,000)
Net cash used in financing activities		(940,000)
Change in Cash and Cash Equivalents	(3,918,015)	6,609,810
Cash and Cash Equivalents, Beginning of Year	9,855,304	3,245,494
Cash and Cash Equivalents, End of Year	\$ 5,937,289	\$ 9,855,304
Reconciliation of Change in Net Assets to Net Cash Provided by		
Operating Activities		
Change in net assets	\$ 27,492,046	\$ 20,574,507
Items not requiring (providing) operating activities cash flows	0.650	
Depreciation	8,658	(77.005)
Amortization of bond premium and issuance costs	2.024.607	(77,985)
Net realized and unrealized losses (gains) on investments	2,824,687	(883,130)
Change in value of Precede Fund, L.C. investments	90,307	(142,600)
Change in investment in KLSD	209,225	(611,718)
Contribution for and gain on repayment of debt	-	(12,521,631)
Changes in Accounts, grants and contributions receivables	(12 000 107)	(2.191.27()
Prepaid expenses	(12,880,197)	(2,181,276)
Accounts payable and accrued expenses	(194,256) 6,071,496	(44,403) (2,308,889)
Deferred revenue	2,185,960	2,082,473
New cools accounted have a second second		
Net cash provided by operating activities	\$ 25,807,926	\$ 3,885,348

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Note 1: Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

The University of Kansas Medical Center Research Institute, Inc. (RI), a not-for-profit organization, manages grants and contracts and earns facilities and administration (F&A) reimbursement and contract administration fees in connection with projects conducted by principal investigators who serve as faculty at the University of Kansas Medical Center (KUMC). The mission of RI is to support the research enterprise and promote scientific discovery in support of KUMC's faculty, staff and students. RI was established by KUMC in 1992; it is governed by a Board of Directors whose membership includes the KU Chancellor, KUMC faculty, KUMC administrators and community members.

Funding for research activities of RI is derived from federal and state grants, privately funded grants provided by corporations and from other not-for-profit organizations and royalties and licensing fees.

RI has four subsidiary corporations: Research Properties, Inc. (RP), KU Center for Technology Commercialization, Inc. (KUCTC), Precede Fund, L.C. (PF) and Kansas Life Sciences Development Company, Inc. (KLSD). All entities are collectively referred to as the "Organization" in the accompanying consolidated financial statements.

RP is tax exempt under IRC Section 501(c)(2) as a title holding corporation.

KUCTC is tax exempt under IRC Section 501(c)(3). KUCTC was organized effective July 1, 2008 to facilitate and support the research and technology transfer operations of the University of Kansas and its affiliated tax exempt research institutions.

Precede Fund, L.C. is a limited liability company established to invest in start-up companies associated with medical research and technology. Precede Fund, L.C. is a majority owned subsidiary as RI holds a 67 percent interest in the capital (73 percent income interest) of the corporation. The minority interest of Precede Fund, L.C., included in net assets as of June 30, 2021 and 2020, was \$138,529 and \$163,441, respectively.

KLSD is a for-profit corporation established to invest in start-up companies associated with medical research and technology. KLSD is a wholly-owned subsidiary of RI.

Although RI is a not-for-profit organization, which is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC), the consolidated accounts of RI are reported in the consolidated financial statements of KUMC due to the commonality of management, control and mission shared by the two organizations. The consolidated financial statements of KUMC are in turn reported in the consolidated financial statements of the University of Kansas (University).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of RI, its wholly owned subsidiaries, RP, KUCTC and KLSD and its majority-owned subsidiary, Precede Fund, L.C. All intercompany transactions and balances have been eliminated in consolidation.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues, expenses, gains, losses and other changes in net assets during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

RI considers all liquid investments with original maturities of three months or less to be cash equivalents. Uninvested cash and cash equivalents included in investment accounts are not considered to be cash and cash equivalents. At June 30, 2021 and 2020, cash equivalents consisted primarily of money market funds.

At times during the year, RI may hold deposits in excess of federal depository insurance limits, resulting in a concentration of credit risk. At June 30, 2021, RI's cash accounts exceeded federally insured limits by approximately \$6.7 million.

Accounts Receivable

Accounts receivable are stated at the amount of consideration from customer, of which RI has an unconditional right to receive plus any accrued and unpaid interest. An allowance for uncollectible receivables is provided for based on management's evaluation of potential uncollectible amounts at year end. Collectability is considered potentially impaired for invoices exceeding six months past due. Factors management considers in establishing the allowance for uncollectible receivables include an aging of accounts receivable and the likelihood of collection of individual accounts based on historical experience and established action plans for collections. The allowance as of June 30, 2021 and 2020, was \$1,530,270 and \$688,817, respectively.

Investments and Net Investment Return

The Organization measures securities, other than investments that qualify for the equity method of accounting, at fair value. The Organization measures equity securities and equity investments without a readily determinable fair value at cost, minus impairment, if any, plus or minus changes resulting from observable price changes for the identical or a similar investment.

For equity securities and equity investments measured under the practicability exception, the Organization performs a qualitative assessment for equity investments without readily determinable fair values considering impairment indicators to evaluate whether an impairment exists. If an impairment exists, the Organization will recognize a loss based on the difference between carrying value and the fair value.

Investment return includes dividend, interest and other investment income; realized and unrealized gains and losses on investments carried at fair value; and realized gains and losses on other investments, less external and direct internal investment expenses. Gains and losses on the sale of securities are recorded on the trade date and are determined using the specific identification method.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Investment return that is initially restricted by donor stipulation and for which the restriction will be satisfied in the same year is recorded as with donor restrictions and then released from restriction. Other investment return is reflected in the consolidated statements of activities with or without donor restrictions based upon the existence and nature of any donor or legally imposed restrictions.

Precede Fund, L.C. and Kansas Life Sciences Development Company, Inc. Investments

Several investments held by Precede Fund, L.C. and KLSD typically have no readily determinable fair value, and are measured at cost and evaluated and adjusted for impairment on an annual basis, plus or minus changes resulting from observable price changes for the identical or similar investments of the same manner. Certain investments may convert to having a readily determinable fair value, such as after an initial public offering. When that occurs, a value is established for the investment based on a quoted market price, and the investment is recorded at fair value. The aggregate of investments held by Precede Fund, L.C. and KLSD at June 30 totaled:

	2021	2020
Precede Fund, L.C.		
Cost basis investments	\$ 302,503	\$ 302,592
Fair value investments	128,867	219,085
	431,370	521,677
KLSD		
Cost basis investments	352,321	695,875
Fair value investments	<u> </u>	619,834
	352,321	1,315,709
	¢ 792 (01	¢ 1.927.297
	\$ 783,691	\$ 1,837,386

The evaluation of impairment requires the use of estimates. It is reasonably possible that changes in events could occur that would change this estimate materially in the near term.

RI did not estimate the fair value of the cost basis investments as management does not consider it practicable to do so since quoted market prices are not available. RI did not identify any events or changes in circumstances that would have a significant adverse effect on the fair value of the investments.

Property and Equipment

Property and equipment acquisitions over \$5,000 are stated at cost less accumulated depreciation and consist of land held for development by RP, as well as leasehold improvements, furniture and fixtures associated with the administrative offices occupied by RI in the KUMC facility and the life sciences incubator managed by RP, and computers and software. Depreciation is charged to expense using the straight-line method over the estimated useful lives of each asset. Assets under leasehold improvements are depreciated over the shorter of the lease term or their respective estimated useful lives.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

The estimated useful lives for each major depreciable classification of property and equipment are as follows:

Leasehold improvements15 yearsFurniture and equipment7 yearsComputers and software3 years

Deferred Revenue

Revenue from fees for clinical trials and direct research contracts is deferred and recognized over the periods to which the fees relate.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor or grantor restrictions.

Net assets without donor restrictions are available for use in general operations and not subject to donor or certain grantor restrictions.

Net assets with donor restrictions are subject to donor or certain grantor restrictions. Some restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other restrictions are perpetual in nature, where the donor or grantor stipulates that resources be maintained in perpetuity.

Clinical Trial and Direct Research Income - Contract Revenues

Clinical trial and direct research income – contract revenues are recognized as RI satisfies performance obligations under its contracts. Revenue is reported at the estimated transaction price, which includes a facilities and administrative charge, or amount that reflects the consideration to which RI expects to be entitled in exchange for providing services. RI determines the transaction price based on standard charges for services provided, reduced by implicit and explicit price concessions, if any. RI determines its estimates of implicit and explicit price concessions based upon contractual agreements, its discount policies and historical experience. The estimated amounts also include variable consideration for payments that are contractually withheld until the end of the research or trial period and paid only once all required work is completed. For the purposes of revenue recognition, variable consideration is assessed on a contract-by-contract basis and the amount included in the transaction price is estimated based on the assessment of RI's anticipated performance and consideration of all information that is reasonably available. Variable consideration is recognized as revenue if and when it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved in the future.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Direct Research Grants, Contributions and Grants and Contributions Receivable

Direct research grants and contributions are provided to RI either with or without restrictions placed on the gift by the donor or grantor. Revenues and net assets are separately reported to reflect the nature of those gifts – with or without donor restrictions.

The value recorded for each grant and contribution is recognized as follows:

Nature of the Gift	Value Recognized
Conditional gifts, with or without restriction Gifts that depend on RI overcoming a donor-imposed barrier to be entitled to the funds	Not recognized until the gift becomes unconditional, <i>i.e.</i> , the donor-imposed barrier is met
Unconditional gifts, with or without restriction Received at date of gift – cash and other assets	Fair value
Received at date of gift – property, equipment and long-lived assets	Estimated fair value
Expected to be collected within one year	Net realizable value
Collected in future years	Initially reported at fair value determined using the discounted present value of estimated future cash flows technique

In addition to the amount initially recognized, revenue for unconditional gifts to be collected in future years is also recognized each year as the present-value discount is amortized using the level-yield method.

Support funded by grants is recognized as RI meets the conditions prescribed by the grant agreement. Facilities and administrative revenue for direct research grants represents indirect costs recovered on research grants and are based on costs reimbursement rates. Rates are negotiated with the U.S. Department of Health and Human Services or the respective private grant donor, as included in each grant agreement. Grant activities and outlays are subject to audit and acceptance by the granting agency and, as a result of such audit, adjustments could be required.

When a donor or grantor stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Absent explicit donor or grantor stipulations for the period of time that long-lived assets must be held, expirations of restrictions for gifts of land, buildings, equipment and other long-lived assets are reported when those assets are placed in service.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Gifts and investment income that are originally restricted by the donor or grantor and for which the restriction is met in the same time period the gift is received are recorded as revenue with donor restrictions and then released from restriction.

Conditional contributions and grants having donor or grantor stipulations which are satisfied in the period the gift is received are recorded as revenue and net assets without donor restrictions.

Income Taxes

RI is exempt from income taxes under Section 501 of the Internal Revenue Code and similar provision of state law. However, RI is subject to federal income tax on any unrelated business taxable income. RI files tax returns in the U.S. federal jurisdiction.

RI follows accounting requirements related to uncertain tax positions. Tax positions taken may include positions that RI is exempt from income taxes or how RI determines its unrelated business income. Uncertain tax positions are recognized if it is more likely than not, based on the technical merits, that the tax position will be realized or sustained upon an examination by the relevant tax authority. No amounts have been recorded at June 30, 2021 and 2020, with respect to uncertain tax positions.

Functional Allocation of Expenses

The costs of supporting the various programs and other activities have been summarized on a functional basis in the consolidated statements of activities. The consolidated statements of functional expenses present the natural classification detail of expenses by function. Certain costs have been allocated among the program and management and general categories based on estimates of time incurred, usage and other relevant factors.

Subsequent Events

Subsequent events have been evaluated through October 6, 2021, which is the date the consolidated financial statements were available to be issued.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Note 2: Investments and Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. There is a hierarchy of three levels of inputs that may be used to measure fair value:

- Level 1 Quoted prices in active markets for identical assets or liabilities
- Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
- **Level 3** Unobservable inputs supported by little or no market activity and are significant to the fair value of the assets or liabilities

The following tables present the fair value measurements of assets recognized in the accompanying consolidated statements of financial position measured at fair value on a recurring basis and the level within the fair value hierarchy in which the fair value measurements fall at June 30, 2021 and 2020:

		Fair Valu	ue Measuremen	ts Using
	Fair Value	Level 1	Level 2	Level 3
<u>June 30, 2021</u>				_
Investments				
Certificates of deposit	\$ 2,308,202	\$ -	\$ 2,308,202	\$ -
Collateralized mortgage				
obligations	89,595,266	-	89,595,266	-
Municipal bonds	5,157,100	-	5,157,100	-
Common stock	889,398	889,398		
Total investments	97,949,966	889,398	97,060,568	
Precede Fund, L.C.				
Common stock	128,867	128,867		
Total	\$ 98,078,833	\$ 1,018,265	\$ 97,060,568	\$ -

Notes to Consolidated Financial Statements June 30, 2021 and 2020

		Fair Value Measurements Using								
	Fair Value	Level 1	Level 2	Level 3						
<u>June 30, 2020</u>				_						
Cash equivalents										
Money market mutual fund	\$ 2,135,769	\$ 2,135,769	\$ -	\$ -						
Investments										
Certificates of deposit	6,345,850	-	6,345,850	-						
Collateralized mortgage										
obligations	64,009,046	-	64,009,046	-						
Common stock	170,708	170,708								
Total investments	70,525,604	2,306,477	70,354,896							
Total investments	70,323,004	2,300,477	70,334,890							
Precede Fund, L.C.										
Common stock	219,085	219,085								
KLSD										
Common stock	619,834	619,834								
Total	\$ 73,500,292	\$ 3,145,396	\$ 70,354,896	\$ -						

Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying consolidated statements of financial position, as well as the general classification of such assets pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the year ended June 30, 2021.

Cash Equivalents, Investments, Precede Fund, L.C. and KLSD

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available, then fair values are estimated by using quoted prices of securities with similar characteristics or independent asset pricing services and pricing models, the inputs of which are market-based or independently sourced market parameters, including, but not limited to, yield curves, interest rates, volatilities, prepayments, defaults, cumulative loss projections and cash flows. Such securities are classified in Level 2 of the valuation hierarchy. In certain cases where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy. No Level 3 securities were held for the years ended June 30, 2021 and 2020.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Note 3: Contributions Receivable

Contributions receivable consisted of the following:

		2021	2020
Due within one year Due in one to five years	\$	1,142,417 1,795,334	\$ 3,179,432 300,000
	<u>\$</u>	2,937,751	\$ 3,479,432

Note 4: Conditional Grants and Contributions

RI has received the following conditional promises to give at June 30, 2021 and 2020 that are not recognized in the consolidated financial statements:

	2021	2020
Conditional promises to give upon incurring qualifying expenses subject to the Uniform Guidance (UG) regulations	\$ 258,509,013	\$ 217,251,860
Conditional promises to give upon receipt of future grantor's board approval	1,420,791	358,719
	\$ 259,929,804	\$ 217,610,579

Note 5: Revenue from Contracts with Customers

Clinical Trials and Fees

RI generally enters into contracts with customers to provide clinical research services with payments based on either achievement of milestones (*e.g.*, number of patients enrolled) or fee-for-service arrangements (*e.g.*, per patient per visit). RI is also entitled to a facilities and administrative fee to cover overhead and reimbursement for investigator fees and out-of-pocket costs associated with these services. At contract inception, RI assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. Generally, all clinical trial contracts are considered a single performance obligation because RI provides a highly-integrated service resulting in a combined output, which is clinical trial data that meets the relevant regulatory standards and can be used by the customer to progress to the next phase of a clinical trial or solicit approval of a treatment by the applicable regulatory body.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

An arrangement is accounted for as a contract within the scope of Topic 606 when RI and its customers approve the contract, are committed to perform their respective obligations, each party can identify its rights regarding the goods or services to be transferred, commercial substance is present, and it is probable that RI will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

For RI's services to meet this criteria, contracts generally need to be written, pending regulatory hurdles required to commence work must be cleared, the study protocol must be completed, the customer must have adequate funding or reasonable path to funding to execute the contracted portion of the study, and the study must be actively moving forward. Once these criteria have been met, it is deemed that RI and its customers are committed to perform their respective obligations. Depending on the timing of when these criteria are met, revenue recognition may vary significantly on a period over period basis.

Revenue is recognized for the single performance obligation over time due to RI's right to payment for work performed to date. The transaction price is the contractually defined amount that includes adjustment for variable consideration such as reimbursable costs, penalties or retainage on periodic billings, which are estimable. The contracts generally provide for the right to invoice the customer as work progresses at contractual rates, either based on units performed or the achievement of billing milestones.

Services under clinical trials are typically billed one month to one quarter in arrears, which may result in an unbilled service asset at period-end. Generally, all of RI's clinical trials are administered and tracked by a related, outside party as opposed to directly by RI. As such, there may be delays between when work is performed and information is provided to RI for billing and recognition. Given the patient data is not maintained or tracked by RI, estimates related to services performed but not yet billed are generally not made as it is not reasonably assured there would not be a significant reversal of revenue, and the related revenue is considered constrained.

The progression of contract performance obligations are measured primarily utilizing the output method per patient per visit basis measure of progress for RI's contracts because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, RI estimates a value to each visit performed under the trial and compares to total visits to date.

In addition, out-of-pocket costs are reimbursed by the customer. Fees are allocated to each distinct month of service using time elapsed as a measure of progress toward the satisfaction of the performance obligation and variable consideration is allocated to the period in which it is incurred.

Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. These contracts require payment of fees for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are agreed to with the customer based on remaining work to be performed. These amounts are included in revenue when RI believes the amount can be estimated reliably and its realization is probable. In evaluating the probability of recognition, RI considers the contractual basis for the settlement amount and the objective evidence available to support the amount.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Direct Research Income - Contracts and Fees

RI generally enters into contracts with customers to provide various research services with payments based on either a fixed fee or cost reimbursement. At contract inception, RI assesses the services promised in the contracts with customers to identify the performance obligations in the arrangement. Generally, all direct research income - contracts are considered a single performance obligation because RI provides a highly-integrated service resulting in a combined output.

Revenue is recognized for the single performance obligation over time due to RI's right to payment for work performed to date. The transaction price is the contractually defined amount that includes adjustment for variable consideration such as reimbursable costs or penalties. The contracts generally provide for the right to invoice the customer as work progresses.

Revenue for performance obligations satisfied over time is recognized ratably over the period based on the cost-to-cost measure. RI believes this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

Contracts generally provide for pricing modifications upon scope of work changes. RI recognizes revenue, at an amount to which it expects to be entitled, related to work performed in connection with scope changes when the underlying services are performed and a binding contractual commitment has been established with the customer. If RI's customers do not agree to contract changes upon changes in RI's scope of work, RI could be exposed to cost overruns and reduced contract profitability.

Transaction Price and Recognition

RI determines the transaction price based on RI's internal pricing guidelines, discount agreements, if any, and negotiations with the client. RI determines its estimates of explicit price concessions based on contractual agreements and its discount policies. RI determines its estimate of implicit price concessions based on its historical collection experience with this class of customers.

From time to time RI will receive overpayments of customer balances resulting in amounts owed back to either the customers or third parties. These amounts are excluded from revenues and are recorded as liabilities until they are refunded. As of June 30, 2021 and 2020, RI did not have any overpayments and related liability.

Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period of the change. For the years ended June 30, 2021 and 2020, no additional revenue was recognized due to changes in its estimates of implicit price concessions, discounts and contractual adjustments for performance obligations satisfied in prior years. Subsequent changes that are determined to be the result of an adverse change in the customer's ability to pay are recorded as bad debt expense.

RI has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the following factors:

• Payors (e.g., customers, governmental programs and others) that have different reimbursement and payment methodologies

Notes to Consolidated Financial Statements June 30, 2021 and 2020

- Geography of the service location
- RI's line of business that provided the service

For the years ended June 30, 2021 and 2020, RI recognized revenue of \$53,569,073 and \$36,531,409, respectively, from services that transfer to the customer over time.

Contract Balances

The Organization does not have any contract assets for the years ended June 30, 2021 and 2020. The following table provides information about the Organization's receivables and contract liabilities from contracts with customers:

	2021	2020
Accounts receivable, beginning of year Accounts receivable, end of year	\$ 7,067,261 8,809,868	\$ 4,829,058 7,067,261
Contract liabilities, beginning of year Contract liabilites, end of year	2,798,524 3,860,293	599,686 2,798,524

Contract Costs

RI has elected to apply the practical expedient provided by FASB ASC 340-40-25-4 and expense as incurred the incremental customer contract acquisition costs for contracts in which the amortization period of the asset that RI otherwise would have recognized is one year or less.

However, incremental costs incurred to obtain customer contracts for which the amortization period of the asset that RI otherwise would have recognized is longer than one year are capitalized and amortized over the life of the contract based on the pattern of revenue recognition from these contracts.

Note 6: Net Assets With Donor Restrictions

Net assets with donor restrictions at June 30 are restricted for the following purposes or periods:

2021	2020
\$ 4,527,492	\$ 3,534,261
2,937,751	3,479,432
\$ 7,465,243	\$ 7,013,693
	\$ 4,527,492 2,937,751

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or occurrence of other events specified by donors.

	2021	2020
Research projects	\$ 4,276,265	\$ 2,898,534

Note 7: Liquidity and Availability

RI regularly monitors liquidity required to meet its operating needs and other contractual commitments, while also striving to maximize the investment of its available funds. RI has various sources of liquidity at its disposal, including cash and cash equivalents and marketable fixed income securities.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, RI considers all expenditures related to its ongoing activities of research as well as the conduct of services undertaken to support those activities as general expenditures. Planned extraordinary expenses are also evaluated to anticipate liquidity needs not included in the regular cadence of general operations.

In addition to financial assets available to meet general expenditures over the next 12 months, RI operates a budget designed to produce an increase in without donor restricted net assets and anticipates collecting sufficient revenue in excess of what is required to cover general expenditures. Refer to the consolidated statements of cash flows which identifies the sources and uses of RI's cash and cash equivalents and shows positive cash and cash equivalents generated by operations for the years ended June 30, 2021 and 2020.

As of June 30, 2021 and 2020, the following financial assets could readily be made available within one year of the consolidated statements of financial position date to meet general expenditures:

	2021	2020
Cash and cash equivalants	\$ 5,937,289	\$ 9,855,304
Accounts receivable, net	8,809,868	7,067,261
Grants receivable	29,233,437	17,596,616
Contributions receivable due within one year	1,142,417	3,179,432
Investments	97,949,966	70,525,604
Interest receivable	241,981	199,531
Financial assets available to meet cash needs for general expenditures within one year	\$ 143,314,958	\$ 108,423,748

Notes to Consolidated Financial Statements June 30, 2021 and 2020

RI receives significant contributions restricted by donors or grantors and considers contributions restricted for programs which are ongoing, major and central to its annual operations to be available to meet cash needs for general expenditures. For the years ended June 30, 2021 and 2020, restricted contributions of \$5,669.909 and \$6,580,382, respectively, were included in financial assets available to meet cash needs for general expenditures within one year.

Note 8: **Related Party Transactions**

University of Kansas and KUMC Operating Agreement

RI has an operating agreement with the University and KUMC. Significant provisions of the agreement are as follows: RI will manage and administer all KUMC extramural grants and contracts (including clinical trials); certain facilities and administrative (indirect) costs collected will be utilized by RI as directed by KUMC; and RI will occupy and use facilities of KUMC based on its agreement that the recovery of facilities and administrative costs and contract administration fees be shared with or used as designated by KUMC.

For the years ended June 30, 2021 and 2020, the following amounts were paid to KUMC and are reflected as "University Support" in the accompanying consolidated statements of activities:

	2021	2020		
Facilities and administrative revenue distributions	\$ 3,466,664	\$	13,493,316	

RI acquires a significant amount of equipment for use through its research projects program. Under the operating agreement noted above, after purchase, ownership of the equipment is transferred to KUMC for further use by its faculty. No depreciation expense is recognized by RI with respect to equipment acquired for use in research projects; instead, the entire amount of such equipment acquisitions are charged to expense and reflected as capital asset donations to KUMC in the accompanying consolidated statements of functional expenses. Additionally, a significant portion of RI's grant expenditures are paid through KUMC's payroll and procurement system, and RI reimburses all such expenditures to KUMC. As of and for the years ended June 30, 2021 and 2020, the following amounts were payable to and expenses incurred on behalf of RI by KUMC:

	 202	2020					
Capital asset donations Personnel and fringe benefit expense Other general grant expenditures	Expense for the Year Ended June 30		Amounts Payable as of June 30		ense for the ear Ended June 30	Amounts Payable as of June 30	
	\$ 2,650,469 73,973,565 11,226,452	\$	4,000,633	\$	3,794,017 67,011,338 11,634,455	\$	3,197,346 -
	\$ 87,850,486	\$	4,000,633	\$	82,439,810	\$	3,197,346

Notes to Consolidated Financial Statements June 30, 2021 and 2020

During the year ended June 30, 2020, the Kansas Development Finance Authority issued Series 2020B Refunding Revenue Bonds in which part of the proceeds were used to refund the 2010N Revenue Bonds previously held by RI. The Series 2020B Refunding Revenue Bonds are reported on the consolidated statement of financial position of KUMC, and as a result, RI recorded contribution revenue without donor restrictions in the amount of \$11,981,773, and a gain on the refunding of the bonds in the amount of \$539,858 was recognized and is included in the consolidated statement of activities for the year ended June 30, 2020.

KUCTC Affiliation Agreement

KUCTC has an agreement to provide technology transfer services to all campuses of the University of Kansas. The University of Kansas Center for Research, Inc. (KUCR) and RI share the cost of operations of KUCTC, based on services provided at each campus. The support RI provides to KUCTC is eliminated in consolidation. KUCR reimburses RI for their support provided to KUCTC, which is included in other income in the consolidated statements of activities for the years ended June 30, 2021 and 2020. During the years ended June 30, 2021 and 2020, KUCR provided the following support:

	 2021	2020			
KUCR revenue support to KUCTC	\$ 740,000	\$	1,187,375		

KUCTC has a revenue sharing agreement with the University and RI. Annually, a calculation is done of net assets in excess of KUCTC's operating expenses for the following fiscal year as defined by the agreement. Such excess is to be distributed to the University and RI, as agreed-upon between the parties. For the years ended June 30, 2021 and 2020, it was agreed-upon by the parties that no amounts would be distributed.

KUCR Sub-Agreements

KUCR enters into various subaward agreements with RI in order for RI to perform certain objectives under the research agreements. As of and for the years ended June 30, 2021 and 2020, the following amounts were owed from and revenues earned from research projects awarded by KUCR:

	2021					2020				
	Direct Research		Amounts Receivable as of June 30		Direct Research Income		Amounts Receivable as of June 30			
KUCR direct research subaward activity to RI	\$	2,158,441	\$	226,848	\$	2,088,407	\$	1,119,048		

Kansas University Endowment Association Research Support

The Kansas University Endowment Association (KUEA) receives funding from other departments under KUMC to provide funding to the RI. Total amounts received from KUEA on behalf of other affiliated departments to support general research activities during the years ended June 30, 2021 and 2020 were \$4,452,282 and \$5,835,289, respectively.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Other

RI is affiliated with several other entities through its relationship with the University and KUMC. Significant transactions with these entities for the years ended June 30, 2021 and 2020, include purchasing supplies and services (*e.g.*, supplies and service fees under research projects, hospital services and lab fees associated with clinical trials, etc.) and entering into subaward agreements under certain research projects. As of and for the years ended June 30, 2021 and 2020, the following amounts were payable to and purchases from other affiliates:

	2021					202	20		
	Expense for the Year Ended June 30		Amounts Payable as of June 30		Ye	ense for the ar Ended June 30	Amounts Payable as of June 30		
General supply purchases and subaward expenses	\$	454,529	\$	23,906	\$	534,952	\$	49,656	

Note 9: Significant Estimates and Concentrations

Accounting principles generally accepted in the United States of America require disclosure of certain significant estimates and current vulnerabilities due to certain concentrations. Those matters include the following:

Accounts Receivable

Estimates associated with the allowance for uncollectible receivables are discussed in *Note 1*.

Contributions Receivable

As of June 30, 2021 and 2020, approximately 47 percent and 59 percent of contributions receivable were due from three donors, respectively.

Direct Research Income and Facilities and Administrative Revenue

During the years ended June 30, 2021 and 2020, approximately 47 percent and 12 percent of total direct research income and the related facilities and administrative revenue was from one grantor or customer, respectively.

Contributions

During the years ended June 30, 2021 and 2020, approximately 46 percent and 63 percent of contribution revenue was from one donor, respectively.

Notes to Consolidated Financial Statements June 30, 2021 and 2020

Investments


RI invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such change could materially affect the amounts reported in the accompanying consolidated statements of financial position.

Precede Fund, L.C. and Kansas Life Sciences Development Company, Inc. Investments

Estimates associated with the value of Precede Fund, L.C. and KLSD investments are discussed in *Note 1*.

Functional Allocation of Expenses

Estimates used to allocate certain costs on a functional basis are discussed in *Note 1*.



Consolidating Statement of Financial Position June 30, 2021

	Researd Institut		Research Properties	KUCTC	KLSD	Eli	minations	Consolidated
sets								
Cash and cash equivalents	\$ 4,540,	937 \$	146,240	\$ 1,246,268	\$ 3,844	\$	-	\$ 5,937,289
Accounts receivable, net	8,809,	736	· -	132	-		-	8,809,868
Grants receivable	29,223,	737	9,700	_	-		-	29,233,43
Contributions receivable	2,937,		· -	_	-		-	2,937,75
Intercompany receivable	423,	668	-	-	-		(423,668)	
Investments	97,829,	117	-	120,849	-		-	97,949,96
Precede Fund, L.C. investments	431,	370	-	-	-		-	431,37
Kansas Life Sciences Development								
Company, Inc. investment	1,	000	-	_	351,321		-	352,32
Interest receivable	241,	981	-	_	-		-	241,98
Prepaid expenses	433,	869	-	_	-		-	433,86
Property and equipment, net	222,	397	266,305	 	 			488,70
Total assets	\$ 145,095,	563 \$	422,245	\$ 1,367,249	\$ 355,165	\$	(423,668)	\$ 146,816,55
abilities and Net Assets								
Liabilities								
Accounts payable	\$ 7,588,	076 \$	58,174	\$ 179,474	\$ 53	\$	-	\$ 7,825,77
Intercompany payable		-	97,363	326,305	-		(423,668)	
Accrued expenses	6,010,	849	-	332,708	-		-	6,343,55
Deferred revenue	5,414,	560		 	 			5,414,56
Total liabilities	19,013,	485	155,537	838,487	 53		(423,668)	19,583,894
Net Assets								
Without donor restrictions	118,616,	835	266,708	528,762	355,112		_	119,767,41
With donor restrictions	7,465,		-	 -	 -		-	7,465,24
Total net assets	126,082,	078	266,708	 528,762	 355,112			127,232,66
Total liabilities and net assets	\$ 145,095,	563 \$	422,245	\$ 1,367,249	\$ 355,165	\$	(423,668)	\$ 146,816,55

Consolidating Statement of Activities Year Ended June 30, 2021

	Research Institute Without Donor Restrictions	Research Institute With Donor Restrictions	Research Properties Without Donor Restrictions	KUCTC Without Donor Restrictions	KLSD Without Donor Restrictions	Eliminations	Consolidated
Revenues, Gains and Other Support							
Direct research income - grants	\$ 71,418,206	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 71,418,206
Direct research income - contracts	6,734,350	· -	-	-	_	-	6,734,350
Total direct research income	78,152,556						78,152,556
	70,102,000						70,102,000
Clinical trials	31,985,435	_	_	_	_	_	31,985,435
Clinical trial IRB and administrative fees	3,452,747	-	-	-	-	-	3,452,747
Facilities and administrative revenue - direct							
research income - grants	26,223,965	_	_	_	_	_	26,223,965
Facilities and administrative revenue - direct	20,225,700						20,225,705
research income - contracts	777,493	_	_	_	_	_	777,493
Facilities and administrative revenue - clinical trials	10,619,048	_	_	_	_	_	10,619,048
Total facilities and administrative revenue	37,620,506						37,620,506
	57,020,000						57,020,000
Contributions	5,901,966	4,727,815	_	_	_	(879,456)	9,750,325
Research Properties, Inc. rental income	60,198	1,727,015	306,636	_	_	(60,198)	306,636
Support for KU Center for Technology	00,170		300,030			(00,170)	300,030
Commercialization, Inc.	447,375	_	_	740,000	_	(447,375)	740,000
Royalties and technology income	399,176	_	_	1,866,778	_	(399,176)	1,866,778
Net investment gain (loss)	(729,360)	-		(49,860)	60,484	(399,170)	(718,736)
Other income	27,316	-	_	(42,800)	00,707	-	27,316
Net assets released from restrictions	4,276,265	(4,276,265)	-	-	-	-	27,310
rvet assets released from restrictions	4,270,203	(4,270,203)					
Total revenues, gains and other support	161,594,180	451,550	306,636	2,556,918	60,484	(1,786,205)	163,183,563
Expenses							
Direct research	120,872,388	_	_	_	_	_	120,872,388
Facilities	8,658	_	_	_	_	_	8,658
University support	3,466,664	_	_	_	_	_	3,466,664
Research Properties, Inc.	5,100,001	_	306,233	_	_	_	306,233
KU Center for Technology			500,255				500,255
Commercialization, Inc royalties and technology	_	_	_	3,047,772	_	(906,749)	2,141,023
Kansas Life Sciences Development				3,017,772		(500,715)	2,111,023
Company, Inc.	_	_	_	_	1,032,651	(879,456)	153,195
Management and general	8.743.356	_	_	_	1,032,031	(075,150)	8,743,356
	0,713,330						0,715,550
Total expenses	133,091,066		306,233	3,047,772	1,032,651	(1,786,205)	135,691,517
Change in Net Assets	28,503,114	451,550	403	(490,854)	(972,167)	-	27,492,046
Net Assets, Beginning of Year	90,113,721	7,013,693	266,305	1,019,616	1,327,279		99,740,614
Net Assets, End of Year	\$ 118,616,835	\$ 7,465,243	\$ 266,708	\$ 528,762	\$ 355,112	\$ -	\$ 127,232,660

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Defense Department of Defense		Research and Development Cluster Research and Development Cluster	Military Medical Research and Development Military Medical Research and Development	12.420 12.420	W81XWH-18-1-0031 W81XWH1810450	s -	\$ 341,873 4,179
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH1910512	170 057	255,763
						178,857	
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH1910360	20,269	205,927
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH1810497	72,915	454,046
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH-18-1-0032	-	77,200
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH-19-1-0047	-	670
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH1610730	-	48,186
Department of Defense	Case Western Reserve University	Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH160503	-	60,263
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH2010637	-	165,239
Department of Defense		Research and Development Cluster	Military Medical Research and Development	12.420	W81XWH2010876	8,773	149,069
						280,814	1,762,415
United States Department of Justice	Michigan State University	Research and Development Cluster	National Institute of Justice Research Evaluation and Development Project Grants	16.560	2019-MU-CX-0094	-	1,200
US Department of Transportation	University of Kansas Center for Research	Research and Development Cluster	Enhanced Mobility of Seniors and Individuals with Disabilities	20.513	FY2017-115	-	(861)
US Department of Transportation	University of Kansas Center for Research	Research and Development Cluster	University Transportation Centers Program	20.701	69A3551747107	-	41,790
National Aeronautics and Space Admininistration		Research and Development Cluster	Space Operations	43.007	NNX13AM62G/80NSSC18K0522		30,778
National Aeronautics and Space Administration National Aeronautics and Space Administration			Space Operations Space Operations	43.007	NNX15AB48G	-	30,778 57.094
National Aeronautics and Space Admininistration		Research and Development Cluster	Space Operations	43.007	NNATSAB48G		87,872
National Science Foundation		Research and Development Cluster	Engineering	47.041	2125030	_	17,880
National Science Foundation		Research and Development Cluster	Engineering	47.041	2129352		8,711
National Science Foundation		Research and Development Cluster	Engineering	47.041	2129617		4,270
rvational Science Foundation		research and Development Cluster	Engineering	47.041	2127017		30,861
National Science Foundation		Research and Development Cluster	Computer and Information Science and Engineering	47.070	2014554	-	67,710
National Science Foundation	Cornell University	Research and Development Cluster	Biological Sciences	47.074	IOS-2005919	-	2,937
National Science Foundation		Research and Development Cluster	Education and Human Resources	47.076	DGE-1518767	_	7,754
National Science Foundation	University of Kansas Center for Research	Research and Development Cluster	Education and Human Resources	47.076	FY2020 020 1907002		75,596
						-	83,350
Department of Education	University of Kansas Center for Research	Research and Development Cluster	Research in Special Education	84.324	R324A200190	-	11,132
Department of Veteran Affairs		Research and Development Cluster	Research and Development	93.RD	1I01BX002567-05	_	34,425
Department of Health and Human Services	University of Illinois at Chicago	Research and Development Cluster	Research and Development	93.RD	75N91019D00016	_	192,131
Department of Health and Human Services	Academy Health	Research and Development Cluster	Research and Development	93.RD	HealthCare Dellivery Research Visiting Scholar	_	27,855
Department of Health and Human Services	VA New York Harbor Healthcare System	Research and Development Cluster	Research and Development	93.RD	VA NYU	-	810
Department of Health and Human Services	ASPR	Research and Development Cluster	Research and Development	93.RD	ASPR	-	(9,616)
Department of Health and Human Services	Veteran Affairs Medical Center	Research and Development Cluster	Research and Development	93.RD	KCVA-IPA	-	7.135
			1			-	252,740
Department of Health and Human Services	University of Miami	Research and Development Cluster	Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	5U01NS107027-02	-	4,014
Department of Health and Human Services	Virginia Commonwealth University	Research and Development Cluster	Food and Drug Administration Research	93.103	END-DM1	-	3,790
Department of Health and Human Services		Research and Development Cluster	Food and Drug Administration Research	93.103	7R01FD003937-02	53,839	113,037
Department of Health and Human Services		Research and Development Cluster	Food and Drug Administration Research	93.103	1R01FD004809-01A2	329,023	439,921
Department of Health and Human Services	University of Missouri	Research and Development Cluster	Food and Drug Administration Research	93.103	R01FD003937	382,862	34,258 591,006
Department of Health and Human Services		Research and Development Cluster	Maternal and Child Health Federal Consolidated Programs	93.110	T73MC06623	11,613	762,155
Department of Health and Human Services	Kansas Department of Health and Environment	Research and Development Cluster	Maternal and Child Health Federal Consolidated Programs	93.110	KS KIDS MAP	,0.0	479,216
Department of Health and Human Services	University of Massachusetts	Research and Development Cluster	Maternal and Child Health Federal Consolidated Programs	93,110	5UA3MC257350800		24,770
1	*					11,613	1,266,141

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services	Johns Hopkins University	Research and Development Cluster	Environmental Health	93.113	48640	s -	\$ 71,563
Department of Health and Human Services	Emory University	Research and Development Cluster	Environmental Health	93.113	7R01ES025145-02	-	29,382
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	1R35GM128562-01	-	391,884
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	R01ES029203	20,589	259,223
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	1R21ES028957-01A1	-	81,831
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	R01ES029280	356,747	499,220
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	K99ES031148	-	91,933
Department of Health and Human Services		Research and Development Cluster	Environmental Health	93.113	R21ES033118	377,336	53,498 1,478,534
Department of Health and Human Services		Research and Development Cluster	Oral Diseases and Disorders Research	93.121	R01DE026955		271,196
Department of Health and Human Services		Research and Development Cluster	Oral Diseases and Disorders Research	93.121	1R21DE026937-10A1	-	258,010
Department of Health and Human Services		Research and Development Cluster	Oral Diseases and Disorders Research	93.121	R01DE026172		573,140 1,102,346
Department of Health and Human Services	Arbor Research Collaborative for Health	Research and Development Cluster	Grants to Increase Organ Donations	93.134	U3EHS32756		44,617
Department of Health and Human Services		Research and Development Cluster	Grants to Increase Organ Donations	93.134	U1333878	3,074,612 3,074,612	3,164,459 3,209,076
Department of Health and Human Services	University of Missouri Kansas City	Research and Development Cluster	Community Programs to Improve Minority Health Grant Program	93.137	ASTWH190088	-	18,537
Department of Health and Human Services	University of Illinois at Chicago	Research and Development Cluster	HIV-Related Training and Technical Assistance	93.145	4U10HA32109-01-01		9,887
Department of Health and Human Services	University of Illinois at Chicago	Research and Development Cluster	HIV-Related Training and Technical Assistance	93.145	6U1OHA29293	23,211	165,869
Department of Health and Human Services	University of Illinois at Chicago	Research and Development Cluster	HIV-Related Training and Technical Assistance	93.145	17541	23,211	23.184
Department of Heatth and Human Services	Chivesity of Himois at Chicago	Research and Development Cluster	Thy-related Halling and Technical Assistance	93.143	17341	23,211	198,940
Department of Health and Human Services	Noguchi Memorial Institute for Medical Research	Research and Development Cluster	Human Genome Research	93.172	1U54HG010275 02	-	5,034
Department of Health and Human Services	University of Missouri	Research and Development Cluster	Research Related to Deafness and Communication Disorders	93,173	1R15DC016383-01		(29)
Department of Health and Human Services	MGH Institute of Health Professions	Research and Development Cluster	Research Related to Deafness and Communication Disorders	93.173	R01DC018823	5,228	27.844
Department of Health and Human Services	CFD Research Corporation	Research and Development Cluster	Research Related to Deafness and Communication Disorders	93.173	R44DC017408	3,220	13,331
						5,228	41,146
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Disabilities Prevention	93.184	NU27DD000006	-	46,367
Department of Health and Human Services		Research and Development Cluster	Telehealth Programs	93.211	5H2ARH30306-04-00	6,000	139,858
Department of Health and Human Services		Research and Development Cluster	Telehealth Programs	93.211	G22RH30363	107,185	248,076
Department of Health and Human Services	University of Kansas Hospital	Research and Development Cluster	Telehealth Programs	93.211	KUMC-1	107,165	45,971
Department of Health and Human Services	*	Research and Development Cluster	Telehealth Programs	93.211	GA5RH37462	189,642	363,931
-			-			302,827	797,836
Department of Health and Human Services	University of Pennsylvania	Research and Development Cluster	Research on Healthcare Costs, Quality and Outcomes	93.226	1R01HS024918-01	_	463
Department of Health and Human Services		Research and Development Cluster	Research on Healthcare Costs, Quality and Outcomes	93.226	1R01HS026134-01A1		187,497
						-	187,960
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Mental Health Research Grants	93.242	FY 2018 -009-M3		49,826
Department of Health and Human Services	,	Research and Development Cluster	Mental Health Research Grants	93.242	R01MM121245	407.313	614,422
						407,313	664,248
Department of Health and Human Services		Research and Development Cluster	Advanced Nursing Education Grant Program	93.247	1T14HP33204-01-00	-	504,573
Department of Health and Human Services		Research and Development Cluster	Poison Center Support and Enhancement Grant	93,253	H4BHS15505	_	135,371
Department of Health and Human Services		Research and Development Cluster	Poison Center Support and Enhancement Grant	93.253	1 H4CHS373520100	-	39,609
1					×		174,980
Department of Health and Human Services	Harvard University	Research and Development Cluster	Occupational Safety and Health Program	93,262	U19OH008861	_	22,626
Department of Health and Human Services	Harvard University	Research and Development Cluster	Occupational Safety and Health Program	93.262	5U19OH008861	-	7,558
Department of Health and Human Services	Harvard University	Research and Development Cluster	Occupational Safety and Health Program	93.262	5U19OH008861-12-00	-	11,667
Department of Health and Human Services	University of Iowa	Research and Development Cluster	Occupational Safety and Health Program	93.262	5U19OH008868-14		7,047
							48,898

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services		Research and Development Cluster	Nurse Faculty Loan Program (NFLP)	93.264	E01HP28798-01-00	s -	\$ 97,422
Department of Health and Human Services Department of Health and Human Services	Rutgers University University of Kansas Center for Research University of Kansas Center for Research	Research and Development Cluster Research and Development Cluster	Alcohol Research Programs	93.273 93.273 93.273 93.273 93.273 93.273 93.273 93.273 93.273	R01AA020518 1R21AA027050-01 R01AA027791 U01AA024733 1R21AA02690-01 5R01AA027586-03 R21AA026025 5R01AA012863-18 R01AA027255		604,340 67,560 5,434 352,705 133,190 422,830 7,639 307,137 7,199
Department of Health and Human Services	University of North Carolina Medical School Lehigh University Lehigh University	Research and Development Cluster Research and Development Cluster	Drug Abuse and Addiction Research Programs	93.279 93.279 93.279 93.279 93.279 93.279 93.279 93.279 93.279	R34DA046598 5 R01 DA042715-05 1R01DA047863-01A1 1R01DA048955 01 R01DA046576 K01DA046576 R01DA0467576 R01DA0467576 R01DA048955 R01AA04786	9,632 39,936 37,057 - - - - - - - - - - - - - - - - - - -	11,031 503,815 77,282 106,449 905,737 164,000 110,913 114,857 70,684 2,064,768
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	U01HL152410	-	5,426
Department of Health and Human Services	Duke Univ-Duke Clinical Research Inst University of Missouri University of Missouri University of Missouri University of Missouri Kansas City University of Arkansas for Medical Sciences University of Missouri	Research and Development Cluster	Minority Health and Health Disparities Research Trans-NIH Research Support	93.307 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	KOIMD014177 3U2COD023375-04S1 IU01HL152410-01 2UG10D024943-03 UL1TR002366 IU01HL152410-02 U01HL152410 ROIDK124664 U24OD024957 IU01HL152410 02	28,511 152,894 - - - - - - - - - - - - - - - - - - -	114,105 3,815 (59) 265,873 2,275,244 30,349 80,198 19,410 258,960 2,014 2,935,804
Department of Health and Human Services	University of Pittsburgh University of Pittsburgh Virginia Commonwealth University University of Georgia Vanderbilt University Medical Center	Research and Development Cluster	National Center for Advancing Translational Sciences National Infrastructure Programs Research Infrastructure Programs Research Infrastructure Programs Research Infrastructure Programs	93.350 93.350 93.350 93.350 93.350 93.350 93.350 93.350 93.350 93.350	5UL1TR001857-03 \$KL2TR002367 TL1TR002368 TL1TR002368 \$UL1TR002366-03 \$UL1TR002366-04 \$UL1TR001857-05 IR21TR00184-01 UL1TR002378 3UL1TR002243-0453 IS100D026793-01 \$R25GM129226-05 \$I00D028598	77,736 173,372 23,551 132,533 199,918 414,400	(1,990) 77,736 527,476 24,545 404,011 287,238 3,442,590 40,276 25,872 8,804 18,225 4,854,783 423,111 93,843 561,215 1078,169

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	e Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services Department of Health and Human Services	University of lowa	Research and Development Cluster Research and Development Cluster Research and Development Cluster Research and Development Cluster Research and Development Cluster	Nursing Research Nursing Research Nursing Research Nursing Research Nursing Research	93.361 93.361 93.361 93.361 93.361	S01306 R01NR014518-05 SR01NR014518-05 1R01NR015743-01A1 1R34NR017793-01	\$	\$ 15,587 321,101 33,445 (2,481) 31,367 399,019
Department of Health and Human Services	Washington University	Research and Development Cluster	Sickle Cell Treatment Demonstration Program	93.365	WU-18-190	-	24,817
Department of Health and Human Services Department of Health and Human Services	Baylor College of Medicine University of California - San Francisco Dartmouth College University of Rochester	Research and Development Cluster Research and Development Cluster	Cancer Cause and Prevention Research	93.393 93.393 93.393 93.393 93.393 93.393 93.393 93.393 93.393 93.393	R01CA185322 R21CA226567 IR01CA207360-01A1 R01CA216265 3R01CA188898-04S1 IR01CA240103-02 R01CA201309 IR01CA226838-01A1 5 R01CA181047-07 R01CA212189 R01CA29437	17,000 - 378,956 25,429 - 421,385	117.500 33.367 28.981 26.347 370.708 387,023 280,047 621,497 338,650 46,796 104,850 2,355,766
Department of Health and Human Services Department of Health and Human Services	University of Kansas Center for Research Kansas State University Fred Hutchinson Cancer Research Center Brown University University of Florida	Research and Development Cluster Research and Development Cluster	Cancer Detection and Diagnosis Research	93.394 93.394 93.394 93.394 93.394 93.394	R01CA243445 R01CA217657 1R03CA253212-01 5 U24 CA086368-20 R01CA253976 R01CA260132 R33CA214333	32,576 - - 9,839 - - 42,415	19,289 88,326 68,408 52,670 10,245 42,206 1,799 282,943
Department of Health and Human Services Department of Health and Human Services	Oregon Health and Sciences University University of Notre Dame Oregon Health and Sciences University Washington University	Research and Development Cluster Research and Development Cluster	Cancer Treatment Research	93.395 93.395 93.395 93.395 93.395 93.395 93.395 93.395	1013080 KUMC_GODWIN R01CA222894 U10CA180888 IR01CA214545-01 B37CA218118 7R01CA231052 02 UGICA239767 R01CA234511	101,736 68,241 24,665 238,000	10,252 150,069 19,269 280,578 763,394 412,601 1,431,897 28,663 3,096,723
Department of Health and Human Services Department of Health and Human Services	Children's Mercy Hospital & Clinics	Research and Development Cluster Research and Development Cluster	Cancer Biology Research	93.396 93.396 93.396 93.396 93.396	R01CA2074450 1R03CA227359-01A1 5R01CA214916-02 1R01CA227838-01A1 R01CA12764 R01CA12764 R01CA214916		95,330 50,843 234,433 500,603 300,951 4,615 1,186,775
Department of Health and Human Services		Research and Development Cluster	Cancer Centers Support Grants	93.397	P30CA168524	387,290	3,192,628
Department of Health and Human Services Department of Health and Human Services	Southwest Oncology Group NRG Oncology Foundation, Inc. NRG Oncology Foundation, Inc. NRG Oncology Foundation, Inc. Michigan State University	Research and Development Cluster Research and Development Cluster Research and Development Cluster Research and Development Cluster Research and Development Cluster	Cancer Control Cancer Control Cancer Control Cancer Control Cancer Control Cancer Control	93.399 93.399 93.399 93.399 93.399	IPA Assignment GOG Studies R-TOG Studies RS004 NSABP Studies UG1CA242632	- - - - -	57,280 782 884 119 31,091 90,156
Department of Health and Human Services		Research and Development Cluster	ACL National Institute on Disability, Independent Living, and Rehabilitation	93.433	90DPKT0003-01-00	(905)	30,826
Department of Health and Human Services		Research and Development Cluster	Research ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	90DPKT0003-02-01	2.896	95.402

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	E	Total Federal xpenditures
						\$ 1,991	\$	126,228
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Pregnancy Assistance Fund Program	93.500	LYFTW	-		145,404
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	University Centers for Excellence in Developmental Disabilities Education, Research, and Service	93.632	0-2994970	-		119,889
Department of Health and Human Services		Research and Development Cluster	Mental and Behavioral Health Education and Training Grants	93.732	M01HP31361	-		132,714
Department of Health and Human Services	University of Missouri St. Louis	Research and Development Cluster	Opioid STR	93.788	H79TI083284	-		27,039
Department of Health and Human Services	University of Texas Health Science at Houston	Research and Development Cluster	Cardiovascular Diseases Research	93.837	UM1HL087318			12.842
Department of Health and Human Services	University of Michigan	Research and Development Cluster	Cardiovascular Diseases Research	93.837	HL137731	_		8,803
Department of Health and Human Services	University of Alabama at Birmingham	Research and Development Cluster	Cardiovascular Diseases Research	93.837	0005 13551 SC004	_		21,975
Department of Health and Human Services	•	Research and Development Cluster	Cardiovascular Diseases Research	93.837	K01HL135472	1.431		133,404
Department of Health and Human Services	Blood Center of Wisconsin	Research and Development Cluster	Cardiovascular Diseases Research	93.837	R01HL068835-13	-		28,903
Department of Health and Human Services	Children's Mercy Hospital & Clinics	Research and Development Cluster	Cardiovascular Diseases Research	93.837	R01HL148463	-		14,900
Department of Health and Human Services		Research and Development Cluster	Cardiovascular Diseases Research	93.837	1R01HL129875-01A1	-		6,783
Department of Health and Human Services		Research and Development Cluster	Cardiovascular Diseases Research	93.837	R01HL131512	25,244		920,751
Department of Health and Human Services		Research and Development Cluster	Cardiovascular Diseases Research	93.837	K01HL149977	-		125,954
Department of Health and Human Services	University of Tennessee Health Science Center	Research and Development Cluster	Cardiovascular Diseases Research	93.837	R01HL141345	-		20,981
Department of Health and Human Services	Indiana University	Research and Development Cluster	Cardiovascular Diseases Research Cardiovascular Diseases Research	93.837	1R01HL154859-01	-		72,858
Department of Health and Human Services	University of North Carolina at Chapel Hill	Research and Development Cluster	Cardiovascular Diseases Research	93.837	OT3HL147154			22,382
						26,675		1,390,536
Department of Health and Human Services	University of North Carolina at Chapel Hill	Research and Development Cluster	Lung Diseases Research	93,838	PrecISE Subawrd No. 5114474-H3KANSAS			2.246
Department of Health and Human Services	Oliversity of North Carolina at Chaper I'lli	Research and Development Cluster	Lung Diseases Research	93.838	UG1HL139119	36,312		2,346 213.523
Department of Health and Human Services	Washington University	Research and Development Cluster	Lung Diseases Research	93.838	5R01HL130876 04	30,312		109,355
Department of Health and Human Services	University of North Carolina Medical School	Research and Development Cluster	Lung Diseases Research	93.838	5115425 5U24HL138998	116,545		169,214
Department of Health and Human Services	Washington University	Research and Development Cluster	Lung Diseases Research	93.838	Pre Award Spending	110,343		2,293
Department of Health and Human Services	,	Research and Development Cluster	Lung Diseases Research	93,838	R01HL133240	61,861		565,500
Department of Health and Human Services		Research and Development Cluster	Lung Diseases Research	93.838	R01HL139365	(18,000)		447,492
Department of Health and Human Services		Research and Development Cluster	Lung Diseases Research	93,838	5F32HL140729-03 REVISED	(,)		57,146
Department of Health and Human Services		Research and Development Cluster	Lung Diseases Research	93.838	5R01HL142543-04			273,095
Department of Health and Human Services		Research and Development Cluster	Lung Diseases Research	93.838	1R01HL152832-01A1 REVISED	_		289,226
Department of Health and Human Services		Research and Development Cluster	Lung Diseases Research	93,838	R01HL157942			16,795
•		1				196,718		2,145,985
Department of Health and Human Services	University of Nebraska Medical Center	Research and Development Cluster	Blood Diseases and Resources Research	93.839	BMT CTN 1101			149
Department of Health and Human Services	Ohio State University	Research and Development Cluster	Blood Diseases and Resources Research	93.839	R01HL137799	_		11,232
Department of Health and Human Services		Research and Development Cluster	Blood Diseases and Resources Research	93.839	7R01HL144552	-		429,981
								441,362
					20112000110			
Department of Health and Human Services	University of Connecticut Health Services	Research and Development Cluster	Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R01AR075143	-		22,330
Department of Health and Human Services	University of Washington	Research and Development Cluster	Arthritis, Musculoskeletal and Skin Diseases Research	93.846 93.846	P50AR065139			96,291
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research	93.846	1R01AR071648-01A1 R01AR071263	46,684		299,903
Department of Health and Human Services Department of Health and Human Services	Brigham and Women's Hospital, Harvard Med School	Research and Development Cluster	Arthritis, Musculoskeletal and Skin Diseases Research Arthritis, Musculoskeletal and Skin Diseases Research	93.846	U56AR075288	211,285		561,758 3.721
Department of Health and Human Services	Brigham and Women's Hospital, Harvard Wed School	Research and Development Cluster	Attititis, Musculoskeietai and Skiii Diseases Research	93.840	U30AR0/3288	257,969		984,003
			mile mile in the second mile in		D. (D. (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)			
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK103872			22,494
Department of Health and Human Services	Hairmain of Tanas Continuent on Mad Control	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	NIH R01DK102142	-		290,755
Department of Health and Human Services	University of Texas Southwestern Med Ctr at Dallas	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	U01DK058369 R01DK100779	400		27,981
Department of Health and Human Services Department of Health and Human Services	Tufts University	Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	K01DK1007/9 5008759SERVUO1DK098245	199,953		201,972
Department of Health and Human Services Department of Health and Human Services	Turis University	Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK103033	-		(1,097)
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	7R01DK103033 7R01DK107131 05	66 100		180,851
Department of Health and Human Services Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	/R01DK10/131 05 R01DK108732	66,100		66,100 188,436
Department of Health and Human Services	Christiny of Ransus Center for Research	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	K23DK109294			177,566
Department of Health and Human Services	University of Oklahoma Health Sciences Center	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK117965			18,541
1	y		, ,	, , , , , , ,				10,541

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	e Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services	Arkansas Children's Hospital Research Institute	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	3466	\$.	\$ 4.713
Department of Health and Human Services	University of Utah	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	10031363-1	5 -	85,142
Department of Health and Human Services	New York University Langone Medical Center	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK114428-01A1	-	226
Department of Health and Human Services	Augusta University	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5U24DK076169-13		39,304
Department of Health and Human Services	Washington University	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5U01DK106853-05	1	(2.166)
Department of Health and Human Services	Purdue University	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK107390-01A1	_	15,629
Department of Health and Human Services	Children's Mercy Hospital & Clinics	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK117296		113,012
Department of Health and Human Services	,	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R56DK112768-01A1		29,412
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK098414	_	495,561
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	DK099611-06	13,721	438,976
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK108088-01A1	-	315,882
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK114121	-	635,487
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK085317-10	-	346,846
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK116669-03	14,043	603,991
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK118220	5,061	543,957
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5K01DK113048-02 1R01DK115850-01	-	123,406
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	5R01DK115850-01 5R01DK116986-03	-	643
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	K01DK112967	85,828	441,551
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK123590-01	39,607	168,920 364,062
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	DP3DK108211	263,108	282,632
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK111693-03	263,108	43,077
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	2R01DK083525-08		246,076
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK108433-05	1	48,053
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK122212-02	_	287,246
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK121497	124,748	532,321
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK113111-05	561,679	739,708
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK115727-02	68,409	365,005
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1R01DK119131-01A1	73,581	348,197
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	P30DK106912	12,607	56,327
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	1F31DK120194-01 U54DK126126		29,693
Department of Health and Human Services Department of Health and Human Services	University of Ghana Medical School	Research and Development Cluster Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	U54DK126126 U54DK116913	42,568	923,129
Department of Health and Human Services Department of Health and Human Services	University of Ghana Medical School	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5R01DK122205-02	-	101,098 318,233
Department of Health and Human Services	Resilio Therapeutics, LLC	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R41DK125183	-	318,233
Department of Health and Human Services	resino merapeanes, EEC	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01DK125465	-	34,139
Department of Health and Human Services	Washington University	Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	U01DK106853		58,410
Department of Health and Human Services		Research and Development Cluster	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	F32DK127693		13.962
1			, , ,			1,571,013	10,399,821
Department of Health and Human Services		Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	5R01NS030853-27	-	486,207
Department of Health and Human Services		Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	5R01NS043314-15	-	72,178
Department of Health and Human Services	Massachusetts General Hospital	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	NN108	-	47,838
Department of Health and Human Services	University of Cincinnati Georgia Regents Research Institute	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	ARCADIA NCT03192215	-	764
Department of Health and Human Services Department of Health and Human Services	Augusta University	Research and Development Cluster Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853 93.853	RI01NS090083 RI01NS090083	-	11,582
Department of Health and Human Services Department of Health and Human Services	Mayo Clinic Jacksonville	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	CREST 2	-	(2,385)
Department of Health and Human Services	Minneapolis Medical Research Foundation	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	U01NS095926	-	1,892 83,171
Department of Health and Human Services	University of Miami	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	2U54NS092091-06 REVISED	-	50,103
Department of Health and Human Services	omreisty of main	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93,853	R21NS104789-02		107,260
Department of Health and Human Services		Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	5K23NS110470-03		132,977
Department of Health and Human Services		Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R00NS101127		158,982
Department of Health and Human Services	University of Rochester	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	1U01NS101944-01	_	11,627
Department of Health and Human Services		Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	1F31NS105442-01A1		9
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01NS118918		67,104
Department of Health and Human Services	University of Michigan	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01NS114251		16,572
Department of Health and Human Services	University of Rochester	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	1U01NS101944-01		86,398
Department of Health and Human Services	University of Cincinnati	Research and Development Cluster	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	1U01NS100699	-	2.194
	•	· ·	-				1,334,473

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	e Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
-	•		•				Experiultures
Department of Health and Human Services Department of Health and Human Services	Ohio University Kansas State University	Research and Development Cluster Research and Development Cluster	Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	1R01AI143743-01 1001831	S -	\$ 31,553
Department of Health and Human Services Department of Health and Human Services	Northwestern University	Research and Development Cluster Research and Development Cluster	Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research			-	5,030
Department of Health and Human Services	Northwestern Oniversity	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855 93.855	HHSN272201600016C 1R21AI139572-01	672	23,650 55,333
Department of Health and Human Services	BCN Biosciences	Research and Development Cluster	Allergy and Infectious Diseases Research	93,855	R43AI145784	6/2	148,548
Department of Health and Human Services	University of Kentucky	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R21AI139956-01		3.113
Department of Health and Human Services	,,	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R01AI121073-01A1	_	229,592
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R21AI153773	_	93,925
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R03AI142361-01A1	-	47,881
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R21AI144923	-	131,011
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R21Al142028	-	145,612
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R21AI144883	-	112,207
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R21AI130613-01A1	-	66,047
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R21AI144564-01	-	212,515
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R01AI150877-01	39,315	371,595
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	R21AI151542 1R21AI144698-01	96,757	212,251
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855	5R01AI147276-03	-	216,702
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R21AI144624	-	436,251 106,578
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	U01AI138323	-	675,687
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93,855	F32AI145158	-	61,184
Department of Health and Human Services	Fred Hutchinson Cancer Research Center	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	3UM1AI68614		305,431
Department of Health and Human Services	University of Kentucky Research Foundation	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	R01AI144126	1	33,246
Department of Health and Human Services	Fred Hutchinson Cancer Research Center	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	3UM1AI068614-14S1	_	1,127,376
Department of Health and Human Services		Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	1R21AI158229-01	_	99.714
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Allergy and Infectious Diseases Research	93.855	A21-0198-S001		11,373
						136,744	4,963,405
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	4R01GM029764-33		481,541
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	2P20GM103418 19	351,141	356,768
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	2P20GM103418 20	1,341,048	2,836,103
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	1 P30 GM118247-01	-,,	880,484
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	NIH78308	-	10,888
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	R25GM078441	-	18,070
Department of Health and Human Services	Fox Chase Cancer Center	Research and Development Cluster	Biomedical Research and Research Training	93.859	FCCC15101-01	-	14,417
Department of Health and Human Services	Rice University	Research and Development Cluster	Biomedical Research and Research Training	93.859	R01GM117138	-	31,427
Department of Health and Human Services	University of Missouri Kansas City	Research and Development Cluster	Biomedical Research and Research Training	93.859	1R01GM121798	-	67,384
Department of Health and Human Services	BBC Entrepreneurial Training Consulting	Research and Development Cluster	Biomedical Research and Research Training	93.859	UT2GM130175	18,752	250,510
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	5R35GM128702-02	-	15,893
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Biomedical Research and Research Training Biomedical Research and Research Training	93.859 93.859	R01GM128241 R01GM115340		206,150
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Biomedical Research and Research Training Biomedical Research and Research Training	93.859	5R01GM077336-11	23,226	138,060
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training Biomedical Research and Research Training	93.859	R01GM126778	11,425 186,840	88,335 453,928
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	5K23GM123320-05	186,840	453,928 160,972
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93,859	7R01GM118660-05	-	297,705
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	3R01GM118589-03S1	53,539	158,301
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	P30GM122731	55,557	19,918
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	5P30GM12273104	_	1,120,858
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	P20GM130423	395,947	2,454,767
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	UG13GM103387	-	(265,984)
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	T32GM138077	-	97,400
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	P20GM103638	-	16,863
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	P20GM103638	-	35,178
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	P20GM103638	-	14,700
Department of Health and Human Services		Research and Development Cluster	Biomedical Research and Research Training	93.859	F32GM140718	-	36,125
Department of Health and Human Services	H CV. C. C. D.	Research and Development Cluster	Biomedical Research and Research Training	93.859	5P20GM103418-21	108,451	296,711
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Biomedical Research and Research Training	93.859	P20GM103638	2,490,369	38,555
						2,490,369	10,332,027

				Federal Assistance Listing	Pass-Through Entity or	Passed Through to	Total Federal
Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Number	Other Identifying Number	Subrecipients	Expenditures
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	5R01HD079642-02	s -	\$ 227,738
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	5T32HD057850-12	-	259,412
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD020676	_	519,880
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1P01HD079363-03	_	22,969
Department of Health and Human Services	Arizona State University	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD093003	_	78,350
Department of Health and Human Services	University of Cincinnati	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD093694	-	214,420
Department of Health and Human Services	University of Minnesota	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R61HD099743	-	124,324
Department of Health and Human Services	University of Arkansas for Medical Sciences	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	U24OD024957	_	86.215
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1000698 M 1	_	283,925
Department of Health and Human Services	Children's Mercy Hospital & Clinics	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD090981	_	8,511
Department of Health and Human Services	University of California Los Angeles	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	HHSN275201300024I	-	91,802
Department of Health and Human Services	Northwestern University	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R01HD093723-01	-	106,990
Department of Health and Human Services	University of California San Diego Medical Center	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD096260	-	27,068
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	5U54HD090216-04	-	(12,191)
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	U54HD090216	-	401,728
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	U54HD090216	-	110,446
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R01HD096144-01	239,781	373,076
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1K99HD099269-01	-	96,972
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD083292	159,437	545,750
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD094545	36,754	401,826
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD094373	32,200	181,092
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R01HD093933-01A1	111,746	266,684
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R01HD086001	-	335,931
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R03HD094608-02		69,962
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865 93.865	R01HD062860 RHD094003A	31,390	240,424
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research	93.865	8UGOD024943-02		89,831
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R21HD099364	(18,000)	55,922
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD062546	-	250,230
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R21HD098880-01	-	379,019 82,367
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD101319	-	82,367 335,329
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	5R13HD083029-04	-	333,329 457
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD099638	36,456	624,278
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	F32HD096809	30,430	59,595
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R21 HD088913	428	2,814
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R21HD087741	420	2,014
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD102623	61,777	314,789
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R21HD104033	4,728	127,287
Department of Health and Human Services		Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	R01HD103888		239,276
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Child Health and Human Development Extramural Research	93.865	1R01HD100364-01A1	-	9,960
						696,697	7,634,458
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	1R01AG043962-01A1		1,539
Department of Health and Human Services	Eli Lilly & Company	Research and Development Cluster	Aging Research	93.866	A4-NIH PO 50747745	-	8.275
Department of Health and Human Services	, , ,	Research and Development Cluster	Aging Research	93.866	2P30AG035982	177,265	2,602,359
Department of Health and Human Services	University of Washington	Research and Development Cluster	Aging Research	93.866	5U01AG016976-20		67,557
Department of Health and Human Services	University of Southern California	Research and Development Cluster	Aging Research	93.866	ADNI3 ATRI-001 PO 50770225	_	38,763
Department of Health and Human Services	University of Southern California	Research and Development Cluster	Aging Research	93.866	R01AG053798	_	20,375
Department of Health and Human Services	University of Texas Southwestern Med Ctr at Dallas	Research and Development Cluster	Aging Research	93.866	1R01AG049749	-	621,510
Department of Health and Human Services	University of Pittsburgh	Research and Development Cluster	Aging Research	93.866	3R01AG053952-04S1	-	1,233,712
Department of Health and Human Services	University of Southern California	Research and Development Cluster	Aging Research	93.866	1U24AF057437-01	-	181,526
Department of Health and Human Services	University of Southern California	Research and Development Cluster	Aging Research	93.866	1R01AG058162-01A1	-	480,068
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	K01AG058785	-	104,112
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Aging Research	93.866	R01AG061187	-	450,731
Department of Health and Human Services	University of Iowa	Research and Development Cluster	Aging Research	93.866	W000853828	-	3,384
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Aging Research	93.866	1R01AG061038-01	-	16,288
Department of Health and Human Services	Columbia University NYC	Research and Development Cluster	Aging Research	93.866	7RF1AG054320-02	-	7,114
Department of Health and Human Services	***	Research and Development Cluster	Aging Research	93.866	1R61AG061881-01	12,605	63,762
Department of Health and Human Services	University of Iowa	Research and Development Cluster	Aging Research	93.866	1R21AG056716-01A1		(255)
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG052954	48,584	606,122

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistance Listing Number	Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	1R21AG066488	s -	\$ 165,348
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R24AG063724	84,672	795,622
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	5K23AG055666-05		199,984
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R21AG058052	-	390,055
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	1R01AG060050-01A1	175,992	488,653
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	4R00AG050490-03		128,490
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG062548	33,316	271,487
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	5R01AG051470-05	(2,100)	(2,100)
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG054486-01A1	-	373,741
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	7R01AG047297-05	10,694	41,935
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	5R01AG063909-03	16,807	574,038
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG060157	-	615,038
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG058530	-	412,538
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG061194	18,613	228,028
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG060733	-	498,051
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG064227	-	538,831
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R21AG061548	-	191,328
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	1K99AG056600-01	-	322,294
Department of Health and Human Services	**	Research and Development Cluster	Aging Research	93.866	R21AG065029	-	61,736
Department of Health and Human Services	University of Iowa	Research and Development Cluster	Aging Research	93.866	1R03AG063170-01	-	10,605
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R21AG066491	-	188,561
Department of Health and Human Services	H. S. COLLL. H. M. C	Research and Development Cluster	Aging Research	93.866	F30AG058397	-	56,557
Department of Health and Human Services	University of Oklahoma Health Sciences Center Duke Univ-Duke Clinical Research Inst	Research and Development Cluster	Aging Research	93.866	1R21AG065720-01	-	10,845
Department of Health and Human Services	Duke Univ-Duke Clinical Research Inst	Research and Development Cluster	Aging Research	93.866	1U19AG065188-01		1,370
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Aging Research	93.866 93.866	R01AG069171 R61AG068483	84,618	298,101
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Aging Research Aging Research	93.866	K01AG065487	22,058	430,623
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster Research and Development Cluster	Aging Research	93.866	R13AG067693	-	85,330
Department of Health and Human Services Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R21AG065755	-	3,815
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	R01AG072895	4.867	79,619 123,654
Department of Health and Human Services	University of Missouri	Research and Development Cluster	Aging Research	93.866	U01AG070928	4,867	
Department of Health and Human Services	University of Minnesota	Research and Development Cluster	Aging Research	93.866	R01AG070728 R01AG069781	-	30,611 58,565
Department of Health and Human Services	Department of Health and Human Services	Research and Development Cluster	Aging Research	93.866	R01AG077036	-	55,263
Department of Health and Human Services	University of Wisconsin	Research and Development Cluster	Aging Research	93.866	R01AG070883	-	35,763
Department of Health and Human Services	Chirtishly of Wisconsin	Research and Development Cluster	Aging Research	93.866	F30AG071349	-	14,158
Department of Health and Human Services	University of Kansas Center for Research	Research and Development Cluster	Aging Research	93.866	R21AG070466	-	5,653
Department of Health and Human Services		Research and Development Cluster	Aging Research	93.866	K01AG072034	-	5,560
Department of Tearth and Truman Services		research and Development Cluster	Aging Research	75.800	R01AG0/2034	687,991	14,296,692
Department of Health and Human Services	University of Utah	Research and Development Cluster	Medical Library Assistance	93,879	UG4LM12344		00.400
Department of Health and Human Services Department of Health and Human Services	University of Utah	Research and Development Cluster Research and Development Cluster	Medical Library Assistance Medical Library Assistance	93.879	UG4LM12344 UG4LM012344	-	80,409
Department of Health and Human Services Department of Health and Human Services	University of Utan	Research and Development Cluster	Medical Library Assistance Medical Library Assistance	93.879	7K01LM012870	-	80,746
Department of Health and Human Services Department of Health and Human Services	University of North Texas Science Center	Research and Development Cluster	Medical Library Assistance Medical Library Assistance	93.879	UG4LM012845	-	131,557
Department of Health and Human Services	Oliversity of North Texas Science Center	Research and Development Cluster	Wedical Library Assistance	93.879	004EM012343		16,750 309,462
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	NU58DP006273	-	71,121
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	NU58DP006273	-	384
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	5NU58DP006273-03-00	-	(2,380)
Department of Health and Human Services	Brigham and Women's Hospital, Harvard Med School	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	5U01HL146002-02	-	65,238
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	NU58DP006273	-	84,471
Department of Health and Human Services	Kansas Department of Heath and Environment	Research and Development Cluster	Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	NU58DP006273		18,626
			·				237,460

Federal Grantor	Pass-Through Grantor	Cluster Title	Program Title	Federal Assistanc Listing Number	e Pass-Through Entity or Other Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Department of Health and Human Services	Northwestern University	Research and Development Cluster	Assistance Programs for Chronic Disease Prevention and Control	93.945	U18DP006120	\$ 20,168	\$ 50,746
Department of Health and Human Services		Research and Development Cluster	Mental Health Disaster Assistance and Emergency Mental Health	93.982	1H79FG000177-01	28,608	489,754
		Total Research and Development Clust	er			13,671,192	91,929,578
US Department of Agriculture			Agricultural Research Basic and Applied Research	10.001	58-3020-0-020	-	4,495
US Department of Agriculture	Mid-America Regional Council		Food Insecurity Nutrition Incentive Grants Program	10.331	Nutrition Incentive Program	11,521	133,358
US Department of the Treasury	Kansas Department of Commerce		COVID-19 Coronavirus Relief Fund	21.019	SARS-CoV-2/COVID	-	599,999
Department of Education	University of Kansas Center for Research		Overseas Programs Special Bilateral Projects	84.015	P015A180104	-	5,944
Department of Education	University of Kansas Center for Research		National Institute on Disability and Rehabilitation Research	84.133	H327S140024	-	(4,063)
Department of Health and Human Services	University of Nebraska Medical Center		Maternal and Child Health Federal Consolidated Programs	93.110	UO1MC17261 10 00	-	34,599
Department of Health and Human Services Department of Health and Human Services Department of Health and Human Services	Kansas Department of Health and Environment Kansas Department of Health and Environment Kansas Department of Health and Environment		Injury Prevention and Control Research and State and Community Based Programs Injury Prevention and Control Research and State and Community Based Programs Injury Prevention and Control Research and State and Community Based Programs	93.136 93.136 93.136	1 NU17CE924998-01-00 NU I 7CE924998-02-00 NUCE924998	- - -	73,262 128,304 41,025 242,591
Department of Health and Human Services	University of Illinois at Chicago		HIV-Related Training and Technical Assistance	93.145	1H1LHA37337-01-00	-	50,000
Department of Health and Human Services			Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	1H79FG0012901	-	87,875
Department of Health and Human Services	Kansas Department of Health and Environment		Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke	93.426	NU58DP006536	-	18,362
Department of Health and Human Services	Kansas Department of Health and Environment		Affordable Care Act (ACA) Maternal, Infant, and Early Childhood Home Visiting Program	93.505	MIECHV	-	373,787
Department of Health and Human Services	Kansas Social Rehabilitation Services	CCDF Cluster	Child Care Mandatory and Matching Funds of the Child Care and Development Fund	93.596	NA	-	694,499
Department of Health and Human Services Department of Health and Human Services Department of Health and Human Services Department of Health and Human Services	The Family Conservancy	Head Start Cluster Head Start Cluster Head Start Cluster Head Start Cluster	Head Start Head Start Head Start Head Start	93.600 93.600 93.600 93.600	07CH70750200 07CH011109 07CH011678 07CH011678	94,369 94,361	31,090 871,112 3,276,885 101,082 4,280,169
Department of Health and Human Services	Kansas Department for Children and Families		Foster Care Title IV-E	93.658	PPS-2019-FFPSB-1	164,542	704,756
Department of Health and Human Services	University of New Mexico		Recovery Act - Comparative Effectiveness Research	93.715	75Q80120C00003	-	300,770
Department of Health and Human Services			Demonstration to Maintain Independence and Employment	93.769	90ALGG0009-01-01	47,367	59,520
Department of Health and Human Services	Kansas Department of Health and Environment		Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	NU58DP006757		178.199
		Total Federal Awards				\$ 13.988.983	\$ 99.694.438

Notes to Schedule of Expenditures of Federal Awards Year Ended June 30, 2021

Notes to Schedule

- 1. The accompanying schedule of expenditures of federal awards (Schedule) includes the federal award activity of RI under programs of the federal government for the year ended June 30, 2021. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of RI, it is not intended to and does not present the financial position, changes in net assets or cash flows of RI.
- 2. Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. RI has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance.



Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

Independent Auditor's Report

Board of Directors University of Kansas Medical Center Research Institute, Inc. Kansas City, Kansas

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of University of Kansas Medical Center Research Institute, Inc. (RI), which comprise the consolidated statement of financial position as of June 30, 2021, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 6, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered RI's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of RI's internal control. Accordingly, we do not express an opinion on the effectiveness of RI's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies, and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did identify certain deficiencies in internal control, described in the accompanying schedule of findings and questioned costs as item 2021-001 that we consider to be a material weakness.

Board of Directors University of Kansas Medical Center Research Institute, Inc. Page 2

Compliance and Other Matters

As part of obtaining reasonable assurance about whether RI's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Management's Response to Finding

Management's response to the finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Management's response was not subjected to the auditing procedures applied in the audit of the consolidated financial statements, and accordingly, we express no opinion on it.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Kansas City, Missouri

BKDLLIP

October 6, 2021



Report on Compliance for the Major Federal Program and Report on Internal Control Over Compliance

Independent Auditor's Report

Board of Directors University of Kansas Medical Center Research Institute, Inc. Kansas City, Kansas

Report on Compliance for the Major Federal Program

We have audited the University of Kansas Medical Center Research Institute, Inc.'s (RI) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on RI's major federal program for the year ended June 30, 2021. RI's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance on RI's major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about RI's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of RI's compliance.



Board of Directors University of Kansas Medical Center Research Institute, Inc. Page 2

Opinion on the Major Federal Program

In our opinion, RI complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended June 30, 2021.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance that are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as item 2021-002. Our opinion on the major federal program is not modified with respect to this matter.

Management's response to the noncompliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Management's response was not subjected to the auditing procedures applied in the audit of compliance, and accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of RI is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered RI's internal control over compliance with the types of requirements that could have a direct and material effect on its major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for its major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of RI's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Board of Directors University of Kansas Medical Center Research Institute, Inc. Page 3

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Kansas City, Missouri November 30, 2021

BKD, LUP

Schedule of Findings and Questioned Costs Year Ended June 30, 2021

Summary of Auditor's Results

Consolidated Financial Statements

1.	The type of report the auditor issued on whether the consolid prepared in accordance with accounting principles generally (GAAP) was: Unmodified Qualified Adverse		
2.	The independent auditor's report on internal control over fin	ancial reporting disc	losed:
	Significant deficiency(ies)?	Yes	None reported ■
	Material weakness(es)?	⊠ Yes	☐ No
3.	Noncompliance considered material to the consolidated final statements was disclosed by the audit?	ncial Yes	⊠ No
Fed	eral Awards		
4.	The independent auditor's report on internal control over corprogram disclosed:	mpliance for major f	ederal awards
	Significant deficiency(ies)?	Yes	None reported
	Material weakness(es)?	Yes	⊠ No
5.	The opinions expressed in the independent auditor's report of awards was: Unmodified Qualified Adverse	on compliance for the	e major federal
6.	The audit disclosed findings required to be reported by 2 CF 200.516(a)?	R Yes	☐ No

Schedule of Findings and Questioned Costs (Continued) Year Ended June 30, 2021

7.	RI's major program was:		
	Cluster/Program		Federal Assistance Listing Number
	· · · · · · · · · · · · · · · · · · ·		
	Research and Development Cluster		Various
8.	The threshold used to distinguish between Type A and Type B program	ns was \$2,99	0,833.
9.	RI qualified as a low-risk auditee?	Yes	⊠ No

Schedule of Findings and Questioned Costs (Continued) Year Ended June 30, 2021

Findings Required to be Reported by Government Auditing Standards

Reference Number	Finding
2021-001	Criteria or Specific Requirement – Management is responsible for establishing and maintaining effective internal control over financial reporting.
	Condition – Audit adjustments were proposed and recorded impacting multiple financial statement areas including accounts payable, revenues and investments.
	Effect – Misstatements could occur within consolidated financial statements due to error or fraud and not be prevented or detected in a timely manner.
	Cause – Due to employee turnover in the accounting department, several financial statement accounts were not appropriately reconciled throughout the year or adjusted at year-end, which resulted in the proposed audit adjustments.
	Recommendation – We recommend management review the areas noted above and establish procedures that will identify and resolve future variances and errors in a timely manner.
	Views of Responsible Officials and Planned Corrective Actions – Management agrees with the stated finding and has implemented a corrective action plan.

Schedule of Findings and Questioned Costs (Continued) Year Ended June 30, 2021

Findings Required to be Reported by Uniform Guidance

Reference Number

Finding

2021-002 **Information on the Federal Program -** Research and Development Cluster, Multiple Federal Grantors, Multiple Award Periods

Criteria or Specific Requirement - Program costs must be paid by non-federal entity funds before submitting a payment request (2 CFR Section 200.305(b)(3)) (*i.e.*, the non-federal entity must disburse funds for program purposes before requesting payment).

Condition – In February 2021, RI processed a duplicate draw relating to numerous research and development grants from the payment management system and did not detect or correct the error until August 2021.

Questioned Costs – The total amount of the duplicate draw was \$1,039,895 and encompassed the following awards:

Federal Assistance	Federal Award Identification		Federal Assistance	Federal Award Identification			Federal Assistance	Federal Award Identification		
Listing	Number	Amount	Listing	Number	Aı	mount	Listing	Number	Aı	mount
02.110	TT03 (C0//02	0 177	02.047	NIII DO1DI(100140	Ф	16.002	02.050	2020 (2) (102 (10 20	Ф	60.115
93.110	T73MC06623	\$ 175	93.847	NIH R01DK102142	\$	16,082	93.859	2P20GM103418 20	\$	68,115
93.113	R01ES029203	6,816	93.847	K23DK109294		50	93.859	R01GM128241		679
93.113	1R21ES028957-01A1	12	93.847	R01DK098414		5,276	93.859	R01GM115340		933
93.121	R01DE026955	305	93.847	DK099611-06		8,522	93.859	5R01GM077336-11		12,694
93.121	R01DE026172	12,120	93.847	5K01DK113048-02		522	93.859	5P30GM12273104		86
93.134	U1333878	118,498	93.847	K01DK112967		3,276	93.865	5T32HD057850-12		412
93.226	1R01HS026134-01A1	153	93.847	1R01DK123590-01		11	93.865	R01HD020676		15,906
93.273	U01AA024733	1,340	93.847	5R01DK108433-05		978	93.865	1K99HD099269-01		121
93.273	1R21AA026904-01	560	93.847	1R01DK122212-02		4,101	93.865	R01HD083292		3
93.273	5R01AA027586-03	4,760	93.847	R01DK121497		46	93.865	R01HD094545		5,406
93.273	5R01AA012863-18	6,701	93.847	5R01DK113111-05		51,316	93.865	R21HD099364		6,478
93.279	5 R01 DA042715-05	16,613	93.847	5R01DK115727-02		2,458	93.865	R01HD101319		57,040
93.279	R01DA046576	5,990	93.847	1R01DK119131-01A1		6,992	93.866	R01AG052954		5,772
93.310	UL1TR002366	443,642	93.853	5R01NS030853-27		2,520	93.866	1R21AG066488		24
93.350	KL2TR002367	6,332	93.853	5R01NS043314-15		619	93.866	R24AG063724		9,636
93.350	TL1TR002368	17,656	93.855	1R01AI121073-01A1		1,125	93.866	1R01AG060050-01A1		12,158
93.350	5UL1TR002366-04	40,044	93.855	R21A1142028		1,664	93.866	R01AG062548		50
93.361	R01NR16255 01A1	80	93.855	R21AI144883		530	93.866	R01AG060157		1,736
93.393	R01CA185322	551	93.855	1R01AI150877-01		1,316	93.866	R01AG061194		437
93.393	R01CA201309	36	93.855	R21AI151542		347	93.866	R01AG060733		1,698
93.395	R37CA218118	1,991	93.855	1R21AI144698-01		13,733	93.866	R01AG064227		3,538
93.396	1R01CA227838-01A1	7,502	93.855	5R01AI147276-03		4,457	93.866	R21AG061548		12,819
93.397	P30CA168524	540	93.855	R21AI144624		3,611	93.866	F30AG058397		120
93.838	R01HL139365	1,944	93.859	4R01GM029764-33		78	93.866	R61AG068483		23
		-,				, -	93.982	1H79FG000177-01		20

\$ 1,039,895

Schedule of Findings and Questioned Costs (Continued) Year Ended June 30, 2021

Reference	,
Number	

Finding

2021-002

Context – During the year-end closing procedures, management identified a duplicate draw that occurred during February 2021. The error was corrected in the payment management system in August 2021 and disclosed to us during the audit process.

Effect – Federal funds were improperly held by RI for approximately seven months.

Cause – After the original draw occurred, the payment was not posted against the invoices and costs included in the request. As a result, the same invoices and costs were included again in the immediately following draw down which resulted in the overpayment.

Recommendation – We recommend that management review the current processes and internal controls for cash management and manke necessary changes to ensure federal draws are processed accurately and reconciled timely.

Views of Responsible Officials and Planned Corrective Actions – Management agrees with the stated finding and has implemented a corrective action plan.



Summary Schedule of Prior Audit Findings Year Ended June 30, 2021

Reference		
Number	Summary of Finding	Status

No matters are reportable.



Corrective Action Plan Year Ended June 30, 2021

In response to the findings noted in the FY2021 audit, the Research Institute provides the following response:

Reference Number	Corrective Action Plan
2021-001	Personnel Responsible for Corrective Action: Paul Toler, Matt Woolley
	Anticipated Completion Date: 11/1/2021
	Corrective Action Plan:

The RI concurs with the findings above and acknowledges that the implementation of a new ERP system (Workday) paired with staff turnover at a critical time created challenges for year-end financial reporting. Mapping of account codes and categorization of transactions made it difficult to compare year over year data from our legacy financial system to Workday. A change in data structure for external support necessitated the development of new financial reports. Further, periodic reconciliations were not completed throughout the year which created reporting delays and adjusting journals at year-end.

In response to the above challenges, we have developed new processes to ensure periodic reconciliations are completed timely and accurately:

- Implementing a change in the process for posting of cash
- Leveraging Workday functionality for completion of periodic reconciliations
- A monthly process of reconciling all balance sheet accounts

The business process changes noted above have been implemented as of 11/1/2021.



Corrective Action Plan (Continued) Year Ended June 30, 2021

Reference Number

Corrective Action Plan

2021-002

Personnel Responsible for Corrective Action: Paul Toler, Matt Woolley

Anticipated Completion Date: 11/1/2021

Corrective Action Plan:

The conditions noted above resulted in the duplicate draw not being identified in a timely manner. Duties have been segregated between the Controller and Accounting Manager to develop a preventative control such that a draw will not occur without being reflected in the RI's general ledger. Also, the new processes noted previously are a detective control that will identify errors in a timely manner and result in immediate correction.

The business process changes noted above have been implemented as of 11/1/2021.